WO2013060258A1 - Clavatine a-c, son procédé de préparation et composition pharmaceutique et son utilisation - Google Patents

Clavatine a-c, son procédé de préparation et composition pharmaceutique et son utilisation Download PDF

Info

Publication number
WO2013060258A1
WO2013060258A1 PCT/CN2012/083360 CN2012083360W WO2013060258A1 WO 2013060258 A1 WO2013060258 A1 WO 2013060258A1 CN 2012083360 W CN2012083360 W CN 2012083360W WO 2013060258 A1 WO2013060258 A1 WO 2013060258A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
compound
acceptable salt
preparation
pharmacologically acceptable
Prior art date
Application number
PCT/CN2012/083360
Other languages
English (en)
Chinese (zh)
Inventor
庾石山
陈乃宏
王晓婧
苑玉和
屈晶
马双刚
李勇
Original Assignee
中国医学科学院药物研究所
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中国医学科学院药物研究所 filed Critical 中国医学科学院药物研究所
Publication of WO2013060258A1 publication Critical patent/WO2013060258A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Definitions

  • the present invention relates to the field of pharmaceutical technology, and in particular, the present invention relates to a class of stone pine alkaloid compounds: Streptococcus alkaloid AC (1-3), a pharmaceutically acceptable salt thereof, a preparation method thereof, and a compound containing the same Pharmaceutical compositions, and the use of such compounds in the preparation of acetylcholinesterase inhibitor drugs, in the preparation of a medicament for the treatment of Alzheimer's disease, and in the preparation of a medicament for the prevention of memory and cognitive decline in the elderly.
  • Streptococcus alkaloid AC 1-3
  • a pharmaceutically acceptable salt thereof a preparation method thereof
  • a compound containing the same Pharmaceutical compositions, and the use of such compounds in the preparation of acetylcholinesterase inhibitor drugs, in the preparation of a medicament for the treatment of Alzheimer's disease, and in the preparation of a medicament for the prevention of memory and cognitive decline in the elderly.
  • AD Alzheimer's disease
  • AD Alzheimer's disease
  • the patient's brain function is gradually declining, memory, abstract thinking ability and language expression decline, inconvenience and other functional disorders, affecting nervous system function, not only bring pain to patients, but also bring many problems to family and society. .
  • AD is a central nervous system degenerative disease characterized by progressive cognitive and memory impairment. It has become the leading cause of death after cardiovascular disease and cancer in developed countries.
  • the main drugs for treating AD include cholinergic drugs, neuronal cell metabolism enhancers, antioxidants, calcium ion antagonists, nerve growth factors, estrogens, anti-inflammatory drugs, and anti-beta amyloid drugs.
  • the most successful method for the treatment of this disease in the clinic is to improve the symptoms of AD patients by increasing the level of cholinergic neurotransmitter-acetylcholine in the central nervous system.
  • Acetylcholinesterase inhibitor specifically inhibits acetylcholinesterase (AChE)
  • AChE acetylcholinesterase
  • the hydrolysis of acetylcholine increases the level of acetylcholine in the brain and becomes the first-line drug for the treatment of AD.
  • Clinically effective drugs such as tacrine, alexin, isgen, galantamine and huperzine A are all acetylcholinesterase inhibitors.
  • the famous natural product, huperzine A is an alkaloid extracted from the Chinese fern phylum (Huperzia serrata (Thunb) Trev., Huperziaceae), which is reversible.
  • a specific inhibitor of cholinesterase which has a selective inhibitory effect on acetylcholinesterase, and has low toxicity and long duration of action. It has been developed as one of the safest and most effective drugs for the treatment of benign memory disorders and Alzheimer's disease. The successful development of a world-class new drug pioneered in China has also enabled us to see the hope of finding new active ingredients from natural products and developing new drugs.
  • Lycopodium japonicum Thunb. is a Lycopodiaceae stone pine plant. It is a traditional Chinese medicine commonly used in China. Its main functions are phlegm dehumidification, sturdy muscles, and it is used for joint pain and flexion and extension. It is found in folk and clinical use that it has a cholinergic side reaction that enhances myocardial contractility, excitatory smooth muscle, and muscle contraction and convulsions, suggesting that it may contain chemical components that have an effect on the cholinergic system.
  • the technical scheme of the present invention attempts to conduct intensive studies on trace alkaloids in Strutgrass, and it is expected to find a novel active ingredient having a novel structure and having an acetylcholinesterase inhibitory action.
  • the technical problem to be solved by the present invention is to provide a new class of compounds of the type: Streptococcus grass AC (l-3) and its pharmacologically acceptable salts.
  • Another aspect of the invention relates to a process for the preparation of the compound ergic acid A-C (1-3). Still another aspect of the invention relates to a pharmaceutical composition comprising a pharmaceutically effective amount of the compound Asparticillin A-C (1-3) as an active ingredient and a carrier commonly used in the pharmaceutical field.
  • Still another aspect of the present invention relates to a compound of sylvestreine AC (1-3) and a composition thereof for use in the preparation of an acetylcholinesterase inhibitor drug, in the preparation of a medicament for treating Alzheimer's disease, and for preparing anti-middle-age memory and cognition The application of drugs with reduced ability.
  • compositions of the compounds of the invention can be prepared according to methods well known in the art.
  • the compound of the present invention may be combined with one or more solid or liquid pharmaceutical excipients and/or adjuvants to provide a suitable administration form or dosage form for use as a medicament.
  • the compound of the present invention or a pharmaceutical composition containing the same may be administered in a unit dosage form, which may be enterally or parenterally, such as oral, intravenous, intramuscular, subcutaneous, intraperitoneal, nasal, oral mucosa, The sputum, lungs and respiratory tract, skin, vagina, rectum, etc., are preferably administered orally.
  • a unit dosage form which may be enterally or parenterally, such as oral, intravenous, intramuscular, subcutaneous, intraperitoneal, nasal, oral mucosa, The sputum, lungs and respiratory tract, skin, vagina, rectum, etc., are preferably administered orally.
  • the dosage form can be a liquid dosage form, a solid dosage form or a semi-solid dosage form.
  • Liquid dosage forms can be solutions (including true and colloidal solutions), emulsions (including o/w, w/o and double emulsions), suspensions, injections (including water injections, powder injections and infusions), eye drops Agents, nasal drops, lotions and tinctures.
  • the solid dosage form can be a tablet (including ordinary tablets, enteric coated tablets, Tablets, dispersible tablets, chewable tablets, effervescent tablets, orally disintegrating tablets), capsules (including hard capsules, soft capsules, enteric capsules), granules, powders, pellets, dropping pills, suppositories, films, Patch, gas (powder) spray, spray, etc.; semi-solid dosage form may be ointment, gel, paste, and the like.
  • the compounds of the present invention can be formulated into common preparations, sustained release preparations, controlled release preparations, targeted preparations, and various microparticle delivery systems.
  • the diluent may be starch, dextrin, sucrose, glucose, lactose, mannitol, sorbitol, xylitol, microcrystalline cellulose, calcium sulfate, calcium hydrogen phosphate, calcium carbonate, etc.
  • the humectant may be water, ethanol, or different Propyl alcohol, etc.
  • the binder may be starch paddle, dextrin, sugar paddle, honey, glucose solution, microcrystalline cellulose, gum arabic paddle, gelatin paddle, sodium carboxymethylcellulose, methylcellulose, hydroxypropyl Methyl cellulose, ethyl cellulose, acrylic resin, carbomer, polyvinylpyrrolidone, polyethylene glycol, etc.
  • disintegrant can be dry starch, microcrystalline cellulose, calcium sulfate, calcium hydrogen phosphate, calcium carbonate, etc.
  • the humectant may be water, ethanol, or different Propyl alcohol, etc.
  • the binder may be starch paddle
  • Tablets may also be further formulated into coated tablets, such as sugar coated tablets, film coated tablets, enteric coated tablets, or bilayer tablets and multilayer tablets.
  • carriers for example, diluents and absorbents such as glucose, lactose, and lakes. Powder, cocoa butter, hydrogenated vegetable oil, polyvinylpyrrolidone, lauric acid polyethylene glycol glyceride, kaolin, talcum powder, etc.; binders such as acacia, tragacanth, gelatin, ethanol, honey, liquid sugar, Rice paste or batter; etc.; disintegrating agents, such as agar powder, dried starch, alginate, sodium dodecylsulfonate, methylcellulose, ethylcellulose, and the like.
  • diluents and absorbents such as glucose, lactose, and lakes.
  • Powder cocoa butter, hydrogenated vegetable oil, polyvinylpyrrolidone, lauric acid polyethylene glycol glyceride, kaolin, talcum powder, etc.
  • binders such as acacia, tragacanth, gelatin, ethanol, honey, liquid sugar,
  • the carrier are, for example, polyethylene glycol, lecithin, cocoa butter, higher alcohols, esters of higher alcohols, gelatin, semi-synthetic glycerides and the like.
  • the active ingredient of the present invention In order to encapsulate the drug delivery unit, the active ingredient of the present invention
  • A-C (1-3) is mixed with the various carriers described above, and the mixture thus obtained is placed in a hard gelatin capsule or soft capsule.
  • the active ingredient of the compound of the present invention can also be formulated into a microcapsule, suspended in an aqueous medium to form a suspension, or can be enclosed in a hard capsule or used as an injection.
  • the compound of the present invention is prepared as an injectable preparation, such as a solution, a suspension solution, an emulsion, a lyophilized powder injection, and the preparation may be aqueous or non-aqueous.
  • an injectable preparation such as a solution, a suspension solution, an emulsion, a lyophilized powder injection
  • the preparation may be aqueous or non-aqueous.
  • One or more pharmaceutically acceptable carriers, diluents, binders, lubricants, preservatives, surfactants or dispersing agents may be included.
  • the diluent may be selected from the group consisting of water, ethanol, polyethylene glycol, 1, 3-propanediol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, polyoxyethylene sorbitan fatty acid ester, and the like.
  • an appropriate amount of sodium chloride, glucose or glycerin may be added to the preparation for injection, and a usual solubilizer, a buffer, a pH adjuster or the like may be added. These excipients are commonly used in the art.
  • coloring agents may also be added to the pharmaceutical preparations as needed.
  • the therapeutic effect is enhanced, and the medicament or the pharmaceutical composition of the present invention can be Administration is by any known method of administration.
  • the dosage of the pharmaceutical composition of the compound of the present invention depends on a number of factors, such as the nature and severity of the disease to be prevented or treated, the sex, age, weight, personality and individual response of the patient or animal, the route of administration, the number of administrations, For therapeutic purposes, the therapeutic dose of the present invention can vary widely. In general, the dosage of the pharmaceutical ingredient of the present invention is well known to those skilled in the art.
  • the prophylactic or therapeutic effect of the present invention can be accomplished by appropriately adjusting the amount of the actual drug contained in the final formulation of the compound composition of the present invention to achieve its therapeutically effective amount.
  • the compound of the present invention is administered in a daily dose ranging from 0.001 to 10 mg/kg body weight in 2-4 divided doses.
  • the compounds or compositions of this invention may be administered alone or in combination with other therapeutic or symptomatic agents and adjusted in dosage.
  • HMBC heteronuclear multi-bond correlation (a two-dimensional nuclear magnetic resonance spectrum for determining the relationship between long-range hydrogen and carbon in a molecule)
  • HSQC heteronuclear single quantum correlation (a two-dimensional nuclear magnetic resonance spectrum for determining the direct relationship between hydrogen and carbon in a molecule)
  • ROESY Rotating Coordinate System Ovhaus Spectrum (a two-dimensional nuclear magnetic resonance spectrum for determining the spatial relationship of hydrogen atoms in a molecule)
  • Fig.1 Extraction and separation of glutinous grass and preparation of acetaminophen AC (1-3)Fig.2 X-ray single crystal diffraction results of acetaminophen AC (1-3) (molecular ellipsoid)
  • the plant of the genus Pinus sylvestris mainly contains components such as alkaloids, terpenoids, organic acids, flavonoids and strontium, and the grasses of the genus Struts are a common plant of the genus Pinus sylvestris. There is no thorough and thorough research.
  • the extracted acid water was adjusted to pH 10 with saturated sodium bicarbonate solution (18 L), extracted with chloroform until the chloroform layer was reacted without alkaloids (4 times, 150 L each time), and the chloroform layer was concentrated to give a total alkaloid 135 g (recorded as B). ).
  • the total alkaloid is chromatographed on an alkaline silica gel column (200-300 mesh, pH 8-9).
  • Test Example 1 Determination of AChE Inhibitory Activity of Strenicin A-C (1-3)
  • Acetylcholinesterase hydrolyzes acetylcholine to produce choline and acetic acid. Choline can react with sulfhydryl chromogenic reagent to form TNB (symmetric trinitrobenzene, Sym-Trinitrobenzene) yellow compound, which is colorimetrically quantified according to color depth. The amount of hydrolysate choline can reflect the activity of cholinesterase. Experimental materials and instruments required:
  • reagent composition includes: reagent one: l mol / L standard application solution; reagent two: substrate; test Agent three: developer solution; reagent four: inhibitor; reagent five: transparent agent; reagent six: stabilizer; reagent seven: normal saline.
  • AC(l-3) has significant acetylcholinesterase inhibitory activity, and its activity is equivalent to or stronger than the positive control substance Huperlin A (HupA).
  • Huperlin A Huperlin A

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention a trait à 3 alcaloïdes (clavatine A-C) isolés de Lycopodium japonicum Thunb., à un sel pharmacodynamiquement acceptable de ceux-ci et à leur procédé de préparation. L'invention a également trait à une composition pharmaceutique contenant cette classe de composés et à l'utilisation de cette classe de composés dans la préparation de médicaments inhibiteurs de l'acétylcholinestérase, de médicaments destinés à traiter la maladie d'Alzheimer et de médicaments permettant de résister à des maladies liées à un déclin de la mémoire et de la capacité cognitive de personnes d'âge mûr et de personnes âgées.
PCT/CN2012/083360 2011-10-24 2012-10-23 Clavatine a-c, son procédé de préparation et composition pharmaceutique et son utilisation WO2013060258A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2011103254504A CN103059043A (zh) 2011-10-24 2011-10-24 伸筋草碱a-c、其制法和其药物组合物与用途
CN201110325450.4 2011-10-24

Publications (1)

Publication Number Publication Date
WO2013060258A1 true WO2013060258A1 (fr) 2013-05-02

Family

ID=48101971

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2012/083360 WO2013060258A1 (fr) 2011-10-24 2012-10-23 Clavatine a-c, son procédé de préparation et composition pharmaceutique et son utilisation

Country Status (2)

Country Link
CN (1) CN103059043A (fr)
WO (1) WO2013060258A1 (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103463022B (zh) * 2013-09-23 2015-07-08 南京广康协生物医药技术有限公司 Lycojaponicumin B在制备治疗回盲肠癌药物中的应用
CN103463035A (zh) * 2013-09-23 2013-12-25 南京广康协生物医药技术有限公司 Lycojaponicumin B在抗疱疹病毒的药物中的应用
CN103463031B (zh) * 2013-09-23 2015-08-19 南京广康协生物医药技术有限公司 Lycojaponicumin B在制备促胰岛素分泌药物中的应用
CN103463046B (zh) * 2013-09-23 2015-11-25 李淑兰 Lycojaponicumin A在制备治疗结直肠癌药物中的应用
CN103463078B (zh) * 2013-09-23 2015-12-23 温州成桥科技有限公司 Lycojaponicumin C在制备治疗肾癌药物中的应用
CN103463057B (zh) * 2013-09-23 2015-08-19 南京广康协生物医药技术有限公司 Lycojaponicumin A在制备治疗登革病毒感染药物中的应用
CN103479633B (zh) * 2013-09-23 2015-12-09 温州成桥科技有限公司 Lycojaponicumin B在制备治疗鼻咽癌药物中的应用
CN103463079B (zh) * 2013-09-23 2015-11-25 赵伟杰 Lycojaponicumin C在制备单胺氧化酶抑制剂药物中的应用
CN103479634B (zh) * 2013-09-23 2015-08-19 南京广康协生物医药技术有限公司 Lycojaponicumin A在制备单胺氧化酶抑制剂药物中的应用
CN103463019B (zh) * 2013-09-23 2015-11-25 付荣 Lycojaponicumin B在制备治疗白血病药物中的应用
CN103463034B (zh) * 2013-09-23 2015-12-02 温州成桥科技有限公司 Lycojaponicumin B在制备治疗卵巢癌药物中的应用
CN103463023B (zh) * 2013-09-23 2015-07-08 南京广康协生物医药技术有限公司 Lycojaponicumin B在制备抗幽门螺杆菌药物中的应用
CN103463061B (zh) * 2013-09-23 2015-11-25 乔良伟 Lycojaponicumin C在制备治疗前列腺癌药物中的应用
CN103463032B (zh) * 2013-09-23 2015-08-19 南京广康协生物医药技术有限公司 Lycojaponicumin A在制备治疗胰腺癌药物中的应用
CN103463037B (zh) * 2013-09-23 2015-09-09 南京广康协生物医药技术有限公司 Lycojaponicumin A在制备抗细菌药物中的应用
CN103479637B (zh) * 2013-09-23 2015-12-02 温州成桥科技有限公司 Lycojaponicumin C在制备抗疱疹病毒的药物中的应用
CN103463076B (zh) * 2013-09-23 2015-12-02 温州成桥科技有限公司 Lycojaponicumin C在制备抗呼吸道合胞病毒的药物中的应用
CN103446128B (zh) * 2013-09-23 2015-12-02 温州成桥科技有限公司 Lycojaponicumin B在制备治疗皮肤癌药物中的应用
CN103463054B (zh) * 2013-09-23 2015-11-25 李淑兰 Lycojaponicumin A在制备治疗膀胱癌药物中的应用
CN103446151B (zh) * 2013-09-23 2016-01-20 温州成桥科技有限公司 Lycojaponicumin C在制备治疗登革病毒感染药物中的应用
CN103446133B (zh) * 2013-09-23 2015-12-02 李淑兰 Lycojaponicumin B在制备治疗舌癌药物中的应用
CN103463040B (zh) * 2013-09-23 2016-03-02 吕洪生 Lycojaponicumin A在制备治疗肾综合征出血热药物中的应用
CN103479630B (zh) * 2013-09-23 2015-12-02 温州成桥科技有限公司 Lycojaponicumin A在制备治疗乳腺癌药物中的应用
CN103446137B (zh) * 2013-09-23 2015-09-16 南京广康协生物医药技术有限公司 Lycojaponicumin A在制备治疗黄热病毒感染药物中的应用
CN103479628B (zh) * 2013-09-23 2015-12-09 温州成桥科技有限公司 Lycojaponicumin A在制备抗疱疹病毒的药物中的应用
CN103446142B (zh) * 2013-09-23 2015-11-25 李淑兰 Lycojaponicumin C在制备治疗胰腺癌药物中的应用
CN103463058B (zh) * 2013-09-23 2015-08-19 南京广康协生物医药技术有限公司 Lycojaponicumin A在治疗胆管癌药物中的应用
CN103446143B (zh) * 2013-09-23 2015-12-09 李彦良 Lycojaponicumin C在制备治疗胃癌药物中的应用
CN103446146B (zh) * 2013-09-23 2016-01-06 隋安奎 Lycojaponicumin C在制备治疗回盲肠癌药物中的应用
CN103463074B (zh) * 2013-09-23 2015-07-08 南京广康协生物医药技术有限公司 Lycojaponicumin C在制备抑制肝脏成纤维细胞增殖药物中的应用
CN103463045B (zh) * 2013-09-23 2015-08-19 南京广康协生物医药技术有限公司 Lycojaponicumin A在制备治疗回盲肠癌药物中的应用
CN103463069B (zh) * 2013-09-23 2015-12-02 温州成桥科技有限公司 Lycojaponicumin C在制备治疗鼻咽癌药物中的应用
CN103463051B (zh) * 2013-09-23 2015-08-19 南京广康协生物医药技术有限公司 Lycojaponicumin A在制备治疗鼻咽癌药物中的应用
CN103446147B (zh) * 2013-09-23 2015-11-25 李景红 Lycojaponicumin C在制备治疗宫颈癌药物中的应用
CN103463067B (zh) * 2013-09-23 2015-12-09 温州成桥科技有限公司 Lycojaponicumin C在制备治疗黄热病毒感染药物中的应用
CN103479629B (zh) * 2013-09-23 2015-09-09 南京广康协生物医药技术有限公司 Lycojaponicumin A在制备抗呼吸道合胞病毒的药物中的应用
CN103463064B (zh) * 2013-09-23 2015-12-09 温州成桥科技有限公司 Lycojaponicumin C在制备治疗白血病药物中的应用
CN103479631B (zh) * 2013-09-23 2015-09-16 南京广康协生物医药技术有限公司 Lycojaponicumin B在制备抗结核菌药物中的应用
CN103446129B (zh) * 2013-09-23 2015-08-19 南京广康协生物医药技术有限公司 Lycojaponicumin A在制备抗结核菌药物中的应用
CN103446135B (zh) * 2013-09-23 2015-09-09 南京广康协生物医药技术有限公司 Lycojaponicumin A在制备抗人体真菌药物中的应用
CN103463018B (zh) * 2013-09-23 2015-11-25 李淑兰 Lycojaponicumin B在制备治疗肾综合征出血热药物中的应用
CN103463024B (zh) * 2013-09-23 2015-12-02 温州成桥科技有限公司 Lycojaponicumin B在制备治疗肾癌药物中的应用
CN103463053B (zh) * 2013-09-23 2015-12-02 温州成桥科技有限公司 Lycojaponicumin A在制备治疗肝癌药物中的应用
CN103446136B (zh) * 2013-09-23 2015-12-02 温州成桥科技有限公司 Lycojaponicumin A在制备抗肺癌转移药物中的应用
CN103463060B (zh) * 2013-09-23 2015-08-19 南京广康协生物医药技术有限公司 Lycojaponicumin C在制备治疗子宫内膜癌药物中的应用
CN103463042B (zh) * 2013-09-23 2015-07-08 南京广康协生物医药技术有限公司 Lycojaponicumin A在制备治疗前列腺癌药物中的应用
CN103463077B (zh) * 2013-09-23 2015-11-25 顾祥茂 Lycojaponicumin C在制备促胰岛素分泌药物中的应用
CN103463029B (zh) * 2013-09-23 2015-07-08 南京广康协生物医药技术有限公司 Lycojaponicumin B在制备抗人体真菌药物中的应用
CN103463048B (zh) * 2013-09-23 2015-08-19 南京广康协生物医药技术有限公司 Lycojaponicumin A在制备促进小肠蠕动药物中的应用
CN103463027B (zh) * 2013-09-23 2015-08-19 南京广康协生物医药技术有限公司 Lycojaponicumin A在治疗喉癌药物中的应用
CN103463056B (zh) * 2013-09-23 2015-08-19 南京广康协生物医药技术有限公司 Lycojaponicumin A在制备治疗舌癌药物中的应用
CN103463044B (zh) * 2013-09-23 2015-12-09 李淑兰 Lycojaponicumin A在制备治疗皮肤癌药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106979A (en) * 1989-02-21 1992-04-21 University Of Pittsburgh Method for the synthesis of huperzine A and analogs thereof and compounds useful therein

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106979A (en) * 1989-02-21 1992-04-21 University Of Pittsburgh Method for the synthesis of huperzine A and analogs thereof and compounds useful therein

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HE, JUAN ET AL.: "Lycojapodine A, a Novel Alkaloid from Lycopodium japonicum", ORGANIC LETTERS, vol. 11, no. 6, 26 February 2009 (2009-02-26), pages 1397 - 1400, XP055066238 *
WANG, XIAOJING ET AL.: "Lycojaponicumins A-C, Three Alkaloids with an Unprecedented Skeleton from Lycopodium japonicum", ORGANIC LETTERS, vol. 14, no. 10, 8 May 2012 (2012-05-08), pages 2614 - 2617, XP055066237 *

Also Published As

Publication number Publication date
CN103059043A (zh) 2013-04-24

Similar Documents

Publication Publication Date Title
WO2013060258A1 (fr) Clavatine a-c, son procédé de préparation et composition pharmaceutique et son utilisation
CN111662281B (zh) 水杨酸类小檗碱型生物碱季铵盐及其制备药物的用途
US6376682B1 (en) Compound with α-glucosidase inhibiting action and method for producing the same
CN108191616B (zh) 白及中具有选择性丁酰胆碱酯酶抑制作用的单体成分及其用途
JP2016508489A (ja) プロトパナキサジオール誘導体、その製造方法及びその応用
EP3409664B1 (fr) Application de dérivés substitués du cinnamamide dans la préparation de médicaments contre l'anxiété
CN109942491A (zh) 附子中具有抗炎镇痛作用的c20二萜生物碱及其用途
CN103012345B (zh) 木犀草素α晶型物质、其制法和其药物组合物与用途
CN101429184B (zh) 木犀草素两种晶型物质、其制法和其药物组合物与用途
CN101429185B (zh) 槲皮素两种晶型物质、其制法和其药物组合物与用途
WO2005116042A1 (fr) Traitement et prevention du cancer a l'aide de nouveaux derives de ginsenosides
KR20210042041A (ko) 페놀라민 b형 결정, 제조 방법과 그의 조성물 및 용도
CN114929682B (zh) 苯并硫代吡喃酮类化合物的盐及其制备方法和用途
KR100564383B1 (ko) 진세노사이드 유도체의 제조방법
CN110092806B (zh) 附子中具有镇痛作用的c19二萜生物碱糖苷及其用途
WO2011003362A1 (fr) Sels de la 13a-(s)-désoxytylophorinine, leurs méthodes de préparation, compositions pharmaceutiques et utilisations
CN113214207A (zh) 橙皮素与甜菜碱共晶物a及制备方法和其组合物与用途
CN103058976B (zh) 槲皮素α晶型物质、其制法和其药物组合物与用途
CN113214209A (zh) 橙皮素与卡马西平共晶物及制备方法和其组合物与用途
CN112279811A (zh) C20二萜生物碱、其制备及治疗疼痛相关疾病的用途
WO2006012779A1 (fr) Extraits de wikstroemia indeca, production de ceux-ci et utilisation de ceux-ci dans la production de produits pharmaceutiques anti-inflammatoires
CN112457284B (zh) 寡聚木脂素类化合物及其制备方法和其药物组合物与用途
CN103450011B (zh) 抗柯萨奇病毒的二萜酸及其制法和其药物组合物与用途
CN112168831B (zh) 一个雷公藤内酯醇衍生物在防治炎症性肠病中的用途
CN109988216B (zh) 白桦脂醇晶d型物质及制备方法和其组合物与用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12844376

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12844376

Country of ref document: EP

Kind code of ref document: A1